Scientists haven’t found a cure for migraines, but they’re better at treating the symptoms. In fact, they’ve made more advances in migraine treatment in the last 2 years than in the previous ...

RFID and Faraday pouches are often overlooked in the world of car security products, but they can be massively effective in keeping your car secure. They don’t offer the same amount of physical ...

Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved to help manage and offer relief for people dealing with migraine headaches with or without aura. Both belong to a ...

SUPER strength nicotine pouches being sold in the UK could put young people at risk of an accidental overdose, experts have warned. The small sachets, which sit snugly under the lip, are mostly ...

This article was featured in One Great Story, New York’s reading recommendation newsletter. Sign up here to get it nightly. When Lauren, a rule-abiding eighth-grader in New York, got her first ...

BBC reporter Katharine Da Costa explains how some illegal imports of nicotine pouches contain very high levels of nicotine High strength nicotine pouches that are being sold illegally in the UK ...

Meanwhile, two oral CGRP inhibitors – AbbVie’s Ubrelvy and BioHaven’s Nurtec – have been launched for the on-demand treatment of acute migraine attacks. These don’t compete with Aimovig ...

It was alleged the providers then tried to persuade their colleagues to prescribe Nurtec to Medicaid and other federal health care beneficiaries — a violation of the Anti-Kickback Statute.

Pharma giant Pfizer has agreed to pay $59 million to settle a federal lawsuit accusing a local biopharmaceutical company of paying “kickbacks” to healthcare providers to induce them to prescribe its ...

Other products such as Eliquis, Nurtec, Vyndaqel and Ibrance helped drive the sales beat, as well. On the flip side, vaccines Prevnar and Abrysvo underperformed expectations. Pfizer expects $1B ...

Nurtec ODT/Vydura globally, up 39% operationally, driven primarily by strong demand in the U.S. and, to a much lesser extent, recent launches in international markets, partially offset by lower ...

This was primarily driven by legacy Seagen, Vyndaqel family, Eliquis, Nurtec ODT/Vydura, and Xtandi, partially offset by lower revenues for Abrysvo, Xeljanz and Oncology biosimilars. Read Next ...